Enliven Therapeutics CFO sells shares worth $25,038

Following these transactions, Hohl holds 13,000 shares of Enliven Therapeutics directly. The company, headquartered in Boulder, specializes in pharmaceutical preparations. With a market capitalization of $1.17 billion and a robust current ratio of 17.44, the company shows strong liquidity despite currently operating at a pre-profit stage. With a market capitalization of $1.17 billion and a robust current ratio of 17.44, the company shows strong liquidity despite currently operating at a pre-profit stage.

Following these transactions, Hohl holds 13,000 shares of Enliven Therapeutics directly. The company, headquartered in Boulder, specializes in pharmaceutical preparations. With a market capitalization of $1.17 billion and a robust current ratio of 17.44, the company shows strong liquidity despite currently operating at a pre-profit stage.

Following these transactions, Hohl holds 13,000 shares of Enliven Therapeutics directly. The company, headquartered in Boulder, specializes in pharmaceutical preparations.

In other recent news, Enliven Therapeutics has been the subject of several analyst reviews. BTIG initiated coverage on shares of Enliven Therapeutics with a Buy rating and a price target of $42.00, emphasizing the company’s development of targeted tyrosine kinase inhibitors (TKIs) for cancer treatment. Clear Street also assigned a Buy rating to the company, setting a price target of $36.00, citing the potential of Enliven’s drug for treating chronic myeloid leukemia (CML).

Baird increased the stock’s price target to $40, maintaining an Outperform rating, following promising data from ongoing trials. Jones Trading gave the biotech firm a Buy rating, predicting worldwide peak sales of approximately $800 million for ELVN-001 by 2036. Meanwhile, H.C. Wainwright maintained a Buy rating on Enliven Therapeutics, following the presentation of promising Phase 1 results for ELVN-001.

Mizuho (NYSE:) reaffirmed its Outperform rating and a $39.00 price target on the company, while TD Cowen held its Buy rating, following updated clinical trial data for Enliven’s Phase Ia study in CML. These recent developments highlight the company’s progress in the biotech industry, with analysts expressing confidence in the company’s ability to advance its drug development programs effectively.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.